About Company Moderna, Inc. is a US-based pharmaceutic and biotech firm located in Cambridge, Massachusetts. Moderna concentrates on vaccine know-how grounded on mRNA, also known as messenger RNA. The vaccine platform of the company thrusts artificial ModRNA (nucleoside-modified messenger RNA) into the human body cells utilizing a covering of solid lipid nanoparticles. Subsequently, the nucleoside-modified messenger RNA rearranges the cells for quick resistant reactions. Moderna, Inc. formulates mRNA curative vaccines that are supplied in lipid nanoparticles, utilizing mRNA together with pseudouridine nucleosides. Test subjects are planned to have better creasing and transformation competence through insertional mutagenesis. The exclusive business merchandise of the firm is the Moderna COVID-19 vaccine. Moderna features twenty-four vaccine test subjects, comprising vaccine test subjects for HIV (human immunodeficiency virus), influenza, the Nipah virus, as well as a 2nd COVID-19 vaccine. This vaccine would be simpler to stock up and distribute in comparison to the prevailing vaccines. 65% of the income of the firm in 2020 was generated from the Biomedical Advanced Research and Development Authority and 24% of the income of the firm was produced from other bureaus of the US Federal Government. In which name was Moderna, Inc. known earlier? The erstwhile name of Moderna, Inc. was ModeRNA Therapeutics and it was known in that name from 2010 to 2018. When was Moderna set up? Moderna was established eleven years back in September 2010. Who are the founders of Moderna? The founders of the company are the following: \tTimothy A. Springer \tDerrick Rossi \tKenneth R. Chien \tRobert S. Langer \tNoubar Afeyan Moderna, Inc. Management Stéphane Bancel, CEO Since 2011 October, Stéphane Bancel has been servings as the Chief Executive Officer of the company. He also constituted a part of the Board of Directors of Moderna since 2011 March. Earlier, Stéphane had a five-year stint as the CEO of bioMérieux SA, a France-based diagnostics firm. From 2000 July to 2006 March, Bancel acted in different positions for Eli Lilly and Company, such as Global Manufacturing Strategy and Supply Chain Executive Director, and Belgium region Managing Director. Before joining Eli Lilly, Stéphane worked in the position of Director of Sales and Marketing for the Asia-Pacific territory for bioMérieux. Presently, Stéphane is a part of the BoD of Indigo. Bancel is also a business enterprise collaborator with Flagship Pioneering. Stéphane has a Master of Science degree from the University of Minnesota in chemical engineering, a Master of Engineering degree from ECP (École Centrale Paris), as well as a Master of Business Administration degree from Harvard Business School. Stephen Hoge, President Stephen Hoge is serving as the President of the company. He heads the comprehensive R&D activities of the organization. Since the nascent phase of Moderna, Stephen has spearheaded all the technological campaigns, counting the formation of its platform and clinical curative domains. Of late, Hoge has taken up the duty for the Clinical Development Office of Moderna. Hoge became a part of the company by the end of 2012. Previously, he was associated with McKinsey & Company. Stephen was a collaborator in healthcare operations. Before joining McKinsey, Stephen served as a house physician in the NYC area. Stephen has a Doctor of Medicine degree with a dissertation from the University of California, San Francisco. He also has a Bachelor of Science degree from Amherst College in neuroscience. Presently, Stephen is a part of the BoD of Axcella Health, Inc. It is a therapeutic-phase biotech firm with its stocks publicly traded on the market. David Meline, Chief Financial Officer As the CFO of Moderna, Meline supervises the business expansion, economic, and commercial enterprise operations of the company. Earlier, from 2014 to 2019, David served as the Executive Vice President and Chief Financial Officer of Amgen. The company had entrusted Feline with the overall responsibility of information technology, treasury, and worldwide commercial operations throughout hundred nations. In this function, David headed a business-wide makeover at the time of growing expansion and output and cutting down the growth cycle period. Before joining Amgen, David had a 6-year stint with 3M Company, where he lately worked in the position of the Senior Vice President and Chief Financial Officer and had the responsibility for the overall financial operations throughout seventy nations where Moderna runs its business. Earlier, David occupied various executive berths with General Motors, such as Chief Financial Officer and Vice President for General Motors North America. For the entire duration of his stint with General Motors, David resided and functioned in 5 continents. David has an MBA degree from the University of Chicago in finance. He also has an MS degree from the London School of Economics in economics and a BS degree from Iowa State University in mechanical engineering. Who are the owners of Moderna, Inc.? The proprietors of the organization are listed below: \tStéphane Bancel (7.9%) \tNoubar Afeyan (12.7%) \tStephen Hoge (1.3%) \tRobert S. Langer (2.9%) How many employees work for Moderna? As of June 2021, more than 1,800 people are employed with the firm. What are the clinical domains on which Moderna is working? Currently, Moderna is working on the following clinical domains: \tImmuno-Oncology \tCommunicable Diseases \tCardiovascular Disorders \tUncommon Diseases \tAutoimmune Disorders What is the capitalization status of Moderna, Inc.? Cash, investiture in saleable securities, and cash correspondents: US $12.2 billion (unaudited as of 30th June 2020). Who are the partners/collaborators of Moderna? The list of partners/collaborators of Moderna is given below: \tLonza \tDARPA \tMerck \tBARDA \tAstraZeneca \tBill and Melinda Gates Foundation \tVertex \tKarolinska Institutet Moderna Stock Performance The common stocks of Moderna, Inc. are traded on the NASDAQ stock exchange with the ticker symbol MRNA. Besides, the stock is a component of the following indices: \tStandard & Poor 500 \tNasdaq-100 On October 26, 2021, Moderna, Inc. closed trading with NASDAQ GS at US $345.74 at 4:00 pm Eastern Daylight Time (EDT). Moderna Financial Performance Consolidated income statement for Moderna, Inc. (figures are unaudited and in million US $ other than per share data) Major landmarks achieved by Moderna 2010 Incorporation of the firm took place. 2011 Operations commenced. 2012 US $40 million equity financing took place. 2013 The company received DARPA funding of up to US $25 million. Partnership with AstraZeneca took place in cancer and cardiometabolic ailments – US $240 million directly, up to forty targets. 2014 US $110 million equity financing took place. Extension to new head office and laboratories at 200 Technology Square took place. Tactical deal with Alexion in uncommon illness – US $100 million straight, up to ten targets took place. 2015 Partnership with Merck in communicable disease – US $50 million equity, US $50 million direct, 5 targets. US $450 million equity funding took place. 2016 Moderna launches its foremost growth test subject in the intratumoral immuno-oncology illness mode, mRNA-2416, programming for OX40-Ligand intratumoral immunotherapy. The company receives Bill and Melinda Gates Foundation funding for AIDS/ HIV - Up to the US $100 million. Merck authorizes supplementary vaccine test subjects. 50/50 partnership with AstraZeneca in immuno-oncology - 2 targets. Moderna launches its foremost growth test subject in its restricted curative mode, mRNA AZD-8601, programming for VEGF-A. Pharmaceutical Product Development, LLC (PPD) partnership took place. The company launches its earliest growth test subject in the anti-fertility sickness mode, mRNA-1440 - an H10N8 influenza vaccine test subject. Moderna commences the first-in-human dose administration for mRNA 1440. 2017 Moderna commences the first-in-human dose administration for mRNA-2416, the OX40 ligand intratumoral immunotherapy. Moderna starts the first-in-human dose administration for mRNA-1647, a vaccine test subject for safeguards from cytomegalovirus. Moderna begins the first-in-human dose administration for mRNA-1653, a polyvalent vaccine for safeguards from parainfluenza virus and human metapneumovirus. In a partnership with DARPA, the company launches its foremost communicable disease curative growth test subject, mRNA-1944, programming an antibody/protein versus Chikungunya virus. Charter ratified for developing 200,000 square feet GMP mRNA scientific production hub in Norwood, Massachusetts, which launched in 2018 July. The company achieved the BARDA sponsorship reward for up to US $125 million for the Zika virus. US $474 million equity funding (comprising US $20 million exchangeable note offered by Vertex) took place. Partnership with Vertex CFTR – US $40 million direct, 1 target (US $20 million cash disbursement, US $20 million exchangeable note investiture) took place. Collaboration with Merck in customized cancer vaccines – US $200 million upfront took place. Partnership with Charles River Laboratories (CRL) took place this year. Moderna launches first-in-human dose administration for mRNA-1851, a test subject for the H7N9 influenza vaccine. 2018 Conclusion of series G US $500 million equity funding happened. Overall cash collected: US $2.5 billion. mRNA-8601 (VEGF) advances to the 2nd stage of scientific growth– 1st Moderna test subject to attain the 2nd stage. The company declares the 1st curative atypical illness growth test subject, mRNA-3704 –designed for methylmalonic academia. Merck and Moderna commence first-in-human dose administration for mRNA-4157, a customized cancer vaccine. Authorization and partnership with AstraZeneca for co-growing/co-marketing AZD7970, an mRNA curative programming for relaxin happened this year. The earliest human statistics of Moderna got issued in Molecular Therapy from the research of mRNA 1440, an H10 vaccine test subject. 2019 Moderna declares dose administration of the earliest monoclonal antibody programmed by mRNA in a scientific experiment. Moderna declares optimistic short-term Stage one statistics for combination vaccine versus PIV3 and hMPV. The common stocks of the company commenced trading on the NASDAQ Global Select Market with the “MRNA” ticker symbol. Moderna unveils its high-tech therapeutic progress location in Norwood, Massachusetts. The viewpoint of Moderna, Inc. According to the views expressed by Stéphane Bancel, the CEO of Moderna, the company thinks that its mRNA platform can work out the most formidable challenges posed by the global healthcare sector, starting from illnesses affecting millions of people to uncommon ailments affecting a handful of individuals, to drugs customized to the personal requirements. Disclaimer: The writer has developed this content with the goal that it functions as an in-depth resource for helping people get a quick look into the affairs of the rapidly transforming business world. This is indeed an outstanding opportunity for both students and professionals to gain knowledge. Earnestly following this form of content will assist keen individuals in building the preparedness required to boost their careers. Still, making a hasty decision might land you in a soup. Staying rational to your investment options is always safe. Any rash decision might impact your finances badly. Always discuss with your investment consultant to accomplish a reliable investment decision.